The therapeutic benefit of these agents appears closely related to the degree of FRα expression in tumor tissue, highlighting the importance of accurate and reproducible immunohistochemical (IHC) assessment [7,8,9,10,11,12,13]. The gene discussed is FOLR1; the disease is neoplasm.